We have shown that a significant reduction in the disease activity of the examined RA patients treated with methotrexate during a 24-month follow-up was associated with the significant downregulation of TNFα gene expression in the blood compared with baseline, which became equal to that in healthy subjects. This evidence concerns the gene TNF and rheumatoid arthritis.